BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ziv-Baran T, Hussey S, Sladek M, Amil Dias J, Martin de Carpi J, Miele E, Veres G, Lionetti P, Koletzko S, Nuti F, Paerregaard A, Kolho KL, Russell RK, Shaoul R, Weiner D, Sigall Boneh R, Escher J, Finnby L, Turner D, Levine A. Response to treatment is more important than disease severity at diagnosis for prediction of early relapse in new-onset paediatric Crohn's disease. Aliment Pharmacol Ther 2018;48:1242-50. [PMID: 30450578 DOI: 10.1111/apt.15016] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Haisma SM, Verkade HJ, Scheenstra R, van der Doef HPJ, Bodewes FAJA, van Rheenen PF. Time-to-reach Target Calprotectin Level in Newly Diagnosed Patients With Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr 2019;69:466-73. [PMID: 31365486 DOI: 10.1097/MPG.0000000000002458] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
2 Grover Z, Alex G. Management of inflammatory bowel disease in children: It is time for an individualised approach. J Paediatr Child Health 2020;56:1677-84. [DOI: 10.1111/jpc.14652] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Ashton JJ, Green Z, Kolimarala V, Beattie RM. Inflammatory bowel disease: long-term therapeutic challenges. Expert Rev Gastroenterol Hepatol 2019;13:1049-63. [PMID: 31657969 DOI: 10.1080/17474124.2019.1685872] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 Ziv-Baran T, Mohr R, Pevni D, Ben-Gal Y. A simple-to-use nomogram to predict long term survival of patients undergoing coronary artery bypass grafting (CABG) using bilateral internal thoracic artery grafting technique. PLoS One 2019;14:e0224310. [PMID: 31648226 DOI: 10.1371/journal.pone.0224310] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
5 van Rheenen PF, Aloi M, Assa A, Bronsky J, Escher JC, Fagerberg UL, Gasparetto M, Gerasimidis K, Griffiths A, Henderson P, Koletzko S, Kolho KL, Levine A, van Limbergen J, Martin de Carpi FJ, Navas-López VM, Oliva S, de Ridder L, Russell RK, Shouval D, Spinelli A, Turner D, Wilson D, Wine E, Ruemmele FM. The Medical Management of Paediatric Crohn's Disease: an ECCO-ESPGHAN Guideline Update. J Crohns Colitis 2020:jjaa161. [PMID: 33026087 DOI: 10.1093/ecco-jcc/jjaa161] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 16.5] [Reference Citation Analysis]
6 Bouhuys M, Lexmond WS, Dijkstra G, Lobatón T, Louis E, van Biervliet S, Groen H, Guardiola J, Rheenen PV. Efficacy of anti-TNF dosing interval lengthening in adolescents and young adults with inflammatory bowel disease in sustained remission (FREE-study): protocol for a partially randomised patient preference trial. BMJ Open 2021;11:e054154. [PMID: 34732500 DOI: 10.1136/bmjopen-2021-054154] [Reference Citation Analysis]
7 Harris RE, Aloi M, de Ridder L, Croft NM, Koletzko S, Levine A, Turner D, Veereman G, Neyt M, Bigot L, Ruemmele FM, Russell RK; PIBD SETQuality consortium and PIBDnet. Protocol for a multinational risk-stratified randomised controlled trial in paediatric Crohn's disease: methotrexate versus azathioprine or adalimumab for maintaining remission in patients at low or high risk for aggressive disease course. BMJ Open 2020;10:e034892. [PMID: 32611737 DOI: 10.1136/bmjopen-2019-034892] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
8 Grover Z. Predicting and preventing complications in children with inflammatory bowel disease. Transl Pediatr 2019;8:70-6. [PMID: 30881900 DOI: 10.21037/tp.2019.01.03] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
9 Moriczi M, Pujol-Muncunill G, Martín-Masot R, Jiménez Treviño S, Segarra Cantón O, Ochoa Sangrador C, Peña Quintana L, González Santana D, Rodríguez Martínez A, Rosell Camps A, Armas H, Barrio J, González de Caldas R, Rodríguez Salas M, Balmaseda Serrano E, Donat Aliaga E, Bodas Pinedo A, Vaquero Sosa E, Vecino López R, Solar Boga A, Moreno Álvarez A, Sánchez Sánchez C, Tolín Hernani M, Gutiérrez Junquera C, Martinón Torres N, Leis Trabazo MR, Eizaguirre FJ, García Peris M, Medina Benítez E, Fernández Caamaño B, Vegas Álvarez AM, Crespo Valderrábano L, Alonso Vicente C, Rubio Santiago J, Galera-Martínez R, García-Romero R, Ros Arnal I, Fernández Cebrián S, Lorenzo Garrido H, Viada Bris JF, Velasco Rodríguez-Belvis M, Bartolomé Porro JM, Blanco Rodríguez M, Barros García P, Botija G, Chicano Marín FJ, La Orden Izquierdo E, Crehuá-Gaudiza E, Navas-López VM, Martín-de-Carpi J. Predictors of Response to Exclusive Enteral Nutrition in Newly Diagnosed Crohn´s Disease in Children: PRESENCE Study from SEGHNP. Nutrients 2020;12:E1012. [PMID: 32272604 DOI: 10.3390/nu12041012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
10 Jongsma MME, Aardoom MA, Cozijnsen MA, van Pieterson M, de Meij T, Groeneweg M, Norbruis OF, Wolters VM, van Wering HM, Hojsak I, Kolho KL, Hummel T, Stapelbroek J, van der Feen C, van Rheenen PF, van Wijk MP, Teklenburg-Roord STA, Schreurs MWJ, Rizopoulos D, Doukas M, Escher JC, Samsom JN, de Ridder L. First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn's disease: an open-label multicentre randomised controlled trial. Gut 2022;71:34-42. [PMID: 33384335 DOI: 10.1136/gutjnl-2020-322339] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 17.0] [Reference Citation Analysis]
11 Konidari A, Dickens D, Pirmohamed M. Inflammatory Bowel Disease: A Personalized Approach. Front Pediatr 2020;8:620545. [PMID: 33643966 DOI: 10.3389/fped.2020.620545] [Reference Citation Analysis]
12 Halligan S, Boone D, Archer L, Ahmad T, Bloom S, Rodriguez-Justo M, Taylor SA, Mallett S. Prognostic biomarkers to identify patients likely to develop severe Crohn's disease: a systematic review. Health Technol Assess 2021;25:1-66. [PMID: 34225839 DOI: 10.3310/hta25450] [Reference Citation Analysis]
13 Aardoom MA, Kemos P, Tindemans I, Aloi M, Koletzko S, Levine A, Turner D, Veereman G, Neyt M, Russell RK, Walters TD, Ruemmele FM, Samsom JN, Croft NM, de Ridder L; PIBD-SETQuality consortium and PIBD-NET. International prospective observational study investigating the disease course and heterogeneity of paediatric-onset inflammatory bowel disease: the protocol of the PIBD-SETQuality inception cohort study. BMJ Open 2020;10:e035538. [PMID: 32611739 DOI: 10.1136/bmjopen-2019-035538] [Reference Citation Analysis]
14 Levine A, Chanchlani N, Hussey S, Ziv-Baran T, Escher JC, Amil Dias J, Veres G, Koletzko S, Turner D, Kolho KL, Paerregaard A, Staiano A, Lionetti P, Nuti F, Sladek M, Shaoul R, Lazowska-Prezeorek I, Martin de Carpi J, Sigall Boneh R, Pfeffer Gik T, Cohen-Dolev N, Russell RK. Complicated Disease and Response to Initial Therapy Predicts Early Surgery in Paediatric Crohn's Disease: Results From the Porto Group GROWTH Study. J Crohns Colitis 2020;14:71-8. [PMID: 31162532 DOI: 10.1093/ecco-jcc/jjz111] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
15 Ashton JJ, Mossotto E, Ennis S, Beattie RM. Personalising medicine in inflammatory bowel disease-current and future perspectives. Transl Pediatr 2019;8:56-69. [PMID: 30881899 DOI: 10.21037/tp.2018.12.03] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
16 Kato J, Yoshida T, Hiraoka S. Prediction of treatment outcome and relapse in inflammatory bowel disease. Expert Rev Clin Immunol 2019;15:667-77. [PMID: 30873890 DOI: 10.1080/1744666X.2019.1593140] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
17 Herman R, Dumnicka P, Pieczarkowski S, Fyderek K. Induction of Remission in Pediatric Crohn's Disease Patients Assessed by the Mucosal Inflammation Noninvasive Index. J Clin Med 2021;10:5613. [PMID: 34884315 DOI: 10.3390/jcm10235613] [Reference Citation Analysis]